SCHD ETF at $35.30: Defensive Strength Faces Rate and Sector Risks

SCHD ETF has outperformed the broader market in a sharp sell-off, but rising Treasury yields and concentrated exposure to semiconductors, healthcare and energy are capping upside. Investors now face a tougher trade-off between dividend income and bond yields.

SCHD ETF has held up better than the broader market during the latest equity sell-off, but its resilience is being tested by higher bond yields and pressure on several of its biggest holdings. The Schwab U.S. Dividend Equity ETF traded at $35.30 on November 7, down 2.5% from its record close of $36.21 reached earlier in the week.

The fund’s relative stability remains notable. While the S&P 500 fell 4.36% and the Nasdaq dropped 5.52% in the sharpest leg of the pullback, SCHD declined 2.18%, underscoring its lower-volatility profile and 0.57 five-year beta.

But the bigger question for investors is whether SCHD can continue to justify its premium as an income-and-defense vehicle when the 10-year Treasury yield has climbed to 4.90%, far above the ETF’s 2.97% trailing yield.

Key Facts

  • SCHD traded at $35.30 on November 7, down from a record close of $36.21 and off 2.5% from that high.
  • The ETF has gained 28.3% on price in 2026, with total return above 34% including dividends.
  • SCHD manages $120.70 billion in assets, charges a 0.06% expense ratio, and has a trailing dividend of $1.05 per share.
  • Healthcare accounts for 15.64% of major holdings, while Texas Instruments is the top position at 4.80% and Qualcomm adds 3.79%.
  • The 10-year Treasury yield at 4.90% stands 1.93 percentage points above SCHD’s 2.97% dividend yield.

SCHD ETF

SCHD tracks the Dow Jones U.S. Dividend 100 Index and owns roughly 100 companies selected for financial quality, dividend consistency, and cash-flow strength. The strategy has attracted significant investor interest in 2026 as market leadership broadened beyond mega-cap growth stocks and investors searched for steadier returns. That shift helped drive SCHD from $27.52 at the start of the year to more than $36 before the recent pullback.

The ETF’s defensive reputation is deserved, but not absolute. Its top 10 holdings make up 41.38% of assets, and that concentration means weakness in a few large positions can materially move the fund. Texas Instruments, Procter & Gamble, Coca-Cola, Chevron, ConocoPhillips, Home Depot, Amgen, UnitedHealth, Abbott Laboratories and PepsiCo dominate the portfolio. That blend creates a mix of stability and cyclical exposure rather than a pure low-risk profile.

Why this matters now is simple: several of SCHD’s key sectors face new headwinds at the same time. Semiconductor stocks have sold off sharply, healthcare faces renewed policy uncertainty after the U.S. midterm outcome, and falling oil prices have reduced momentum for energy names. At the same time, rising Treasury yields are making dividend ETFs less compelling for investors focused primarily on income.

SCHD is still behaving defensively, but higher rates and concentrated sector bets mean defense no longer guarantees upside.

Where the pressure is building

Technology exposure is one underappreciated risk in SCHD. Texas Instruments and Qualcomm together account for 8.59% of assets, a sizable weight for investors who may view the fund as a consumer-staples-and-healthcare income vehicle. When the Philadelphia semiconductor index dropped more than 12%, those holdings added volatility to a fund often bought for stability.

Healthcare is another important variable. Amgen, UnitedHealth, Abbott and Merck together represent 15.64% of major holdings. Any expansion of drug-pricing pressure, Medicare reimbursement changes, or insurance-sector regulation could affect sentiment toward these names, even if earnings effects take longer to appear. For a dividend ETF that depends on durable cash generation, policy risk can weigh on valuations before it hits payouts.

Implications for Investors

For portfolio construction, SCHD still offers clear strengths. Its expense ratio is just 0.06%, the underlying companies are generally profitable and established, and the ETF has historically provided lower volatility than the broader market. Consumer staples holdings such as Procter & Gamble, Coca-Cola and PepsiCo continue to anchor the fund and help cushion market drawdowns. That makes SCHD relevant for investors seeking equity exposure with less downside sensitivity than the S&P 500.

Still, the rate backdrop changes the comparison set. With the 10-year Treasury yielding 4.90% and short-term instruments near 4%, investors can now earn higher nominal income from bonds without taking equity risk. SCHD’s appeal therefore depends less on current yield and more on dividend growth plus capital appreciation. That is where the recent slowdown matters: dividend growth over the past 12 months was just 1.95%, well below the fund’s longer-term pace.

Valuation also deserves attention. SCHD trades at 18.20 times trailing earnings and 14.67 times forward earnings, lower than the broad market but less of a bargain after its 2026 rally. If rates stay elevated, multiple expansion looks limited. Future returns may depend more heavily on earnings resilience in staples and healthcare, a stabilization in chip stocks, and whether the December dividend confirms healthier income growth heading into 2027.

Near term, investors are likely to watch the December 9 Federal Reserve decision, Treasury yield direction, and the ETF’s next dividend announcement. A return above $36.21 would suggest renewed momentum, while a move toward $34 could indicate that higher yields and sector-specific risks are starting to outweigh SCHD’s defensive advantages.

Ultima Markets